Jane Street’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Jane Street’s Portfolio LABP Stock Details LABP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,483	Closed	-$7.41K	–	10368
2022 Q4	$7.41K	Buy	+1,483	New	+$5.68K	﹤0.01%	8810
2022 Q3	–	Sell	-2,096	Closed	-$15K	–	10785
2022 Q2	$15K	Buy	+2,096	New	+$19.1K	﹤0.01%	9236

Other funds holding LABP

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jane Street's LABP Position: Q1 2023 in Review

Jane Street sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q1 2023, closing a stake of 1,483 shares — an estimated $7.41K sold.

Jane Street first reported a position in LABP in Q2 2022 and held it in 2 quarters. The position peaked at $15K in Q2 2022. 20 funds tracked by Wall St. Rank hold LABP as of Q1 2023.

Jane Street reported no remaining Landos Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Jane Street sold 1,483 Landos Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $7.41K.
Jane Street first reported a position in Landos Biopharma, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
Jane Street's Landos Biopharma, Inc. Common Stock position peaked at $15K in Q2 2022.
20 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q1 2023.

Based on Jane Street's 13F filing for Q1 2023, filed 16 May 2023.